Preoperative Bevacizumab in Combination With Paclitaxel and Carboplatin in Surgically Resectable Non-Small Cell Lung Cancer

被引：3
|
作者：
Bertino, Erin [1 ]
Villalona-Calero, Miguel A. [1 ]
Ross, Patrick [2 ]
Grever, Michael [3 ]
Otterson, Gregory A. [3 ]
机构：
[1] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA
来源：
ANNALS OF THORACIC SURGERY | 2011年 / 91卷 / 02期
关键词：
TRIAL; SURGERY; CHEMOTHERAPY;
D O I：
10.1016/j.athoracsur.2010.07.047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：640 / 640
页数：1
相关论文
共 50 条
  • [31] Intrapleural combination bevacizumab with cisplatin therapy for non-small cell lung cancer caused by non-small cell lung cancer
    Du, Nan
    Zhao, Hui
    Wang, Haibin
    Li, Xiaosong
    Ma, Junxun
    Fan, Zhongyi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Combination therapy with carboplatin and paclitaxel for small cell lung cancer
    Mouri, Atsuto
    Yamaguchi, Ou
    Miyauchi, Sachiko
    Shiono, Ayako
    Utsugi, Harue
    Nishihara, Fuyumi
    Murayama, Yoshitake
    Kagamu, Hiroshi
    Kobayashi, Kunihiko
    RESPIRATORY INVESTIGATION, 2019, 57 (01) : 34 - 39
  • [33] A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
    Hata, Akito
    Iwasawa, Shunichiro
    Sasaki, Yusuke
    Tajima, Kosei
    Chiba, Yasutaka
    ADVANCES IN THERAPY, 2024, 41 (09) : 3520 - 3538
  • [34] Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Tadahiro Yamadori
    Keiko Nakao
    Kazuhiro Asami
    Tomomi Yasue
    Tomoyuki Otsuka
    Takayuki Shiroyama
    Naoko Morishita
    Hidekazu Suzuki
    Norio Okamoto
    Kyoichi Okishio
    Tomoya Kawaguchi
    Shinji Atagi
    Ichiro Kawase
    Tomonori Hirashima
    Medical Oncology, 2013, 30
  • [35] Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Ding, T.
    Li, Z. -T.
    Zhang, X.
    Shi, Y. -T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (16) : 3723 - 3729
  • [36] Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer
    Yamasaki, Masahiro
    Murakami, Isao
    Nakano, Kikuo
    Doi, Mihoko
    Kitaguchi, Souichi
    Kondo, Tomohiro
    Sakurai, Joji
    Hattori, Noboru
    Arita, Ken-Ichi
    ANTICANCER RESEARCH, 2017, 37 (02) : 923 - 928
  • [37] THE COMBINATION CHEMOTHERAPY OF BEVACIZUMAB PLUS GEMCITABINE AND CARBOPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER
    Kim, Taekyu
    Ahn, Young Mi
    Nam, Seung-hyun
    Kim, Bong-seog
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [38] Prognostic Impact of Immune Cell Biomarkers in Surgically Resectable Non-Small Cell Lung Cancer
    Tuminello, S.
    Veluswamy, R.
    Petralia, F.
    Wang, P.
    Flores, R.
    Van Gerwen, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S254 - S255
  • [39] Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin
    Branco, Helena
    Oliveira, Julio
    Antunes, Catarina
    Santos, Lucio L.
    Vasconcelos, Maria Helena
    Xavier, Cristina P. R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
  • [40] Preoperative thrombocytosis in surgically treated patients with non-small cell lung cancer
    Skorek, Pawel
    Stepien, Konrad
    Fila, Marcin
    Hauer, Jolanta
    Kuzdzal, Jaroslaw
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2018, 128 (09): : 512 - 517
12345